Blog

Cell therapy and gene therapy news: updates from some of our biopharmaceutical partners

by Vineti | August 8, 2019

 

We're always excited to support the innovation pursued by our biopharmeutical partners as they work toward improved patient outcomes. Here are just a few of the notable cell therapy and gene therapy updates from the past month:

 

Tessa Therapeutics and China-Singapore Guangzhou Knowledge City Form Landmark US$120 Million Joint Venture in China to Develop Innovative Cell Therapies for Cancer

SINGAPORE – 13 June 2019 – Tessa Therapeutics (Tessa), a clinical-stage cell therapy company focused on the development of autologous and allogeneic therapies to treat cancer, announced today that it will establish a joint venture with China-Singapore Guangzhou Knowledge City (CSGKC). The joint venture will be the sole licensee of Tessa’s cell therapies for research, clinical development and commercialization in China.

Read more.

 

 

Adaptimmune Starts SPEARHEAD-1 Trial with ADP-A2M4 SPEAR T-cells for patients with Synovial Sarcoma or MRCLS

PHILADELPHIA and OXFORDSHIRE, United Kingdom, July 25, 2019 (GLOBE NEWSWIRE) -- Adaptimmune Therapeutics plc (Nasdaq:ADAP), a leader in T-cell therapy to treat cancer, has started its SPEARHEAD-1 trial with ADP-A2M4 SPEAR T‑cells for patients with synovial sarcoma or myxoid/round cell liposarcoma (MRCLS). Earlier this year, Adaptimmune presented compelling data with responses observed in synovial sarcoma patients treated in the ADP-A2M4 pilot study.


Read more.
 

 

Marker Therapeutics Reports Interim Results of its MultiTAA T Cell Therapy in Patients with Pancreatic Adenocarcinoma at AACR

San Francisco, CA—July 20, 2019—Marker Therapeutics, Inc. (Nasdaq:MRKR), a clinical-stage immuno-oncology company specializing in the development of next-generation T cell-based immunotherapies for the treatment of hematological malignancies and solid tumor indications, today announced interim data from an ongoing investigator-sponsored clinical trial led by Baylor College of Medicine, evaluating the Company’s MultiTAA T cell therapy in patients with pancreatic adenocarcinoma.

Read more.

 

 

And in case you missed any of the following, Vineti also have some news of its own, including international recognition as a technology leader from the World Economic Forum and our partnership with industry leader Lonza.

 

 

Vineti makes coordination, delivery, and traceability of these types of cell therapies, gene therapies, and neoantigen cancer vaccines possible -- safely. If you’d like to see our platform in action, please contact us to schedule a demo.

 

 

 

Back to Blog